drugset / Trial / NCT03257644
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics (PK) of topical ruxolitinib cream applied to pediatric subjects (age ≥ 2 to 17 years) with atopic dermatitis (AD).
Timeline
- Start
- 2017-09-21
- Primary completion
- 2020-10-07
- Completion
- 2020-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 0.5 % | Topical |
| Subject | Ruxolitinib | Small molecule | 0.75 % | Topical |
| Subject | Ruxolitinib | Small molecule | 1.5 % | Topical |